{"count": 33, "results": [{"_id": "36315128", "pmid": 36315128, "pmcid": "PMC9623477", "title": "Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease", "journal": "JAMA Neurol", "authors": ["Stevens KN", "Creanor S", "Jeffery A", "Whone A", "Zajicek J", "Foggo A", "Jones B", "Chapman R", "Cocking L", "Wilks J", "Webb D", "Carroll C", "PD STAT Study Group"], "date": "2022-12-01T00:00:00Z", "doi": "10.1001/jamaneurol.2022.3718", "meta_date_publication": "2022 Dec 1", "meta_volume": "79", "meta_issue": "12", "meta_pages": "1232-1241", "score": 50273.867, "text_hl": "Evaluation of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ as a Disease-Modifying Treatment for @SPECIES_9606 @@@Patients@@@ With @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson Disease@@@", "citations": {"NLM": "Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, Jones B, Chapman R, Cocking L, Wilks J, Webb D, Carroll C, PD STAT Study Group. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease JAMA Neurol. 2022 Dec 1;79(12):1232-1241. PMID: 36315128", "BibTeX": "@article{36315128, title={Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease}, author={Stevens KN and Creanor S and Jeffery A and Whone A and Zajicek J and Foggo A and Jones B and Chapman R and Cocking L and Wilks J and Webb D and Carroll C and PD STAT Study Group}, journal={JAMA Neurol}, volume={79}, number={12}, pages={1232-1241}}"}}, {"_id": "37513826", "pmid": 37513826, "pmcid": "PMC10385015", "title": "The Potential Therapeutic Application of Simvastatin for Brain Complications and Mechanisms of Action", "journal": "Pharmaceuticals (Basel)", "authors": ["Vuu YM", "Kadar Shahib A", "Rastegar M"], "date": "2023-06-22T00:00:00Z", "doi": "10.3390/ph16070914", "meta_date_publication": "2023 Jun 22", "meta_volume": "16", "meta_issue": "7", "meta_pages": "", "score": 50268.508, "text_hl": "Recent studies have suggested that @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ could be a promising therapeutic option for different @DISEASE_Brain_Diseases @DISEASE_MESH:D001927 @@@brain complications@@@ and diseases ranging from @DISEASE_Brain_Neoplasms @DISEASE_MESH:D001932 @@@brain tumors@@@ (i.e., @DISEASE_Medulloblastoma @DISEASE_MESH:D008527 @@@medulloblastoma@@@ and @DISEASE_Glioblastoma @DISEASE_MESH:D005909 @@@glioblastoma@@@) to @DISEASE_Neurologic_Manifestations @DISEASE_MESH:D009461 @@@neurological disorders@@@ (i.e., @DISEASE_Alzheimer_Disease @DISEASE_MESH:D000544 @@@Alzheimer's disease@@@, @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@, and @DISEASE_Huntington_Disease @DISEASE_MESH:D006816 @@@Huntington's disease@@@). ", "citations": {"NLM": "Vuu YM, Kadar Shahib A, Rastegar M. The Potential Therapeutic Application of Simvastatin for Brain Complications and Mechanisms of Action Pharmaceuticals (Basel). 2023 Jun 22;16(7):. PMID: 37513826", "BibTeX": "@article{37513826, title={The Potential Therapeutic Application of Simvastatin for Brain Complications and Mechanisms of Action}, author={Vuu YM and Kadar Shahib A and Rastegar M}, journal={Pharmaceuticals (Basel)}, volume={16}, number={7}}"}}, {"_id": "37445592", "pmid": 37445592, "pmcid": "PMC10341642", "title": "Repurposing Simvastatin in Parkinson's Disease Model: Protection Is throughout Modulation of the Neuro-Inflammatory Response in the Substantia nigra", "journal": "Int J Mol Sci", "authors": ["Rubio-Osornio M", "León CTG", "Montes S", "Rubio C", "Ríos C", "Monroy A", "Morales-Montor J"], "date": "2023-06-21T00:00:00Z", "doi": "10.3390/ijms241310414", "meta_date_publication": "2023 Jun 21", "meta_volume": "24", "meta_issue": "13", "meta_pages": "", "score": 50260.207, "text_hl": "Repurposing @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ in @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's Disease@@@ Model: Protection Is throughout Modulation of the Neuro-@DISEASE_Inflammation @DISEASE_MESH:D007249 @@@Inflammatory@@@ Response in the Substantia nigra", "citations": {"NLM": "Rubio-Osornio M, León CTG, Montes S, Rubio C, Ríos C, Monroy A, Morales-Montor J. Repurposing Simvastatin in Parkinson's Disease Model: Protection Is throughout Modulation of the Neuro-Inflammatory Response in the Substantia nigra Int J Mol Sci. 2023 Jun 21;24(13):. PMID: 37445592", "BibTeX": "@article{37445592, title={Repurposing Simvastatin in Parkinson's Disease Model: Protection Is throughout Modulation of the Neuro-Inflammatory Response in the Substantia nigra}, author={Rubio-Osornio M and León CTG and Montes S and Rubio C and Ríos C and Monroy A and Morales-Montor J}, journal={Int J Mol Sci}, volume={24}, number={13}}"}}, {"_id": "33735898", "pmid": 33735898, "title": "Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes.", "journal": "Neuroimmunomodulation", "authors": ["Du RW", "Bu WG"], "date": "2021-01-01T00:00:00Z", "doi": "10.1159/000513678", "meta_date_publication": "2021", "meta_volume": "28", "meta_issue": "2", "meta_pages": "82-89", "score": 50257.598, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ Prevents @DISEASE_Neurodegenerative_Diseases @DISEASE_MESH:D019636 @@@Neurodegeneration@@@ in the @CHEMICAL_1_Methyl_4_phenyl_1_2_3_6_tetrahydropyridine @CHEMICAL_MESH:D015632 @@@MPTP@@@ @SPECIES_10090 @@@Mouse@@@ Model of @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's Disease@@@ via Inhibition of A1 Reactive Astrocytes.", "citations": {"NLM": "Du RW, Bu WG. Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes. Neuroimmunomodulation. 2021;28(2):82-89. PMID: 33735898", "BibTeX": "@article{33735898, title={Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes.}, author={Du RW and Bu WG}, journal={Neuroimmunomodulation}, volume={28}, number={2}, pages={82-89}}"}}, {"_id": "35466952", "pmid": 35466952, "pmcid": "PMC9398073", "title": "Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT", "journal": "J Parkinsons Dis", "authors": ["Kehagia AA", "North TK", "Grose J", "Jeffery AN", "Cocking L", "Chapman R", "Carroll C"], "date": "2022-01-01T00:00:00Z", "doi": "10.3233/JPD-212987", "meta_date_publication": "2022", "meta_volume": "12", "meta_issue": "5", "meta_pages": "1591-1604", "score": 50256.543, "text_hl": "A qualitative study embedded in the @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@PD@@@ STAT multi-centre randomised controlled trial of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ for neuroprotection in @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@PD@@@ explored the motivators, barriers and challenges of participants, care partners and research staff.", "citations": {"NLM": "Kehagia AA, North TK, Grose J, Jeffery AN, Cocking L, Chapman R, Carroll C. Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT J Parkinsons Dis. 2022;12(5):1591-1604. PMID: 35466952", "BibTeX": "@article{35466952, title={Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT}, author={Kehagia AA and North TK and Grose J and Jeffery AN and Cocking L and Chapman R and Carroll C}, journal={J Parkinsons Dis}, volume={12}, number={5}, pages={1591-1604}}"}}, {"_id": "32016638", "pmid": 32016638, "title": "Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.", "journal": "Cell Mol Neurobiol", "authors": ["Yan J", "Liu A", "Fan H", "Qiao L", "Wu J", "Shen M", "Lai X", "Huang J"], "date": "2020-10-01T00:00:00Z", "doi": "10.1007/s10571-020-00804-7", "meta_date_publication": "2020 Oct", "meta_volume": "40", "meta_issue": "7", "meta_pages": "1155-1164", "score": 50252.41, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ can play a positive role in @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@. ", "citations": {"NLM": "Yan J, Liu A, Fan H, Qiao L, Wu J, Shen M, Lai X, Huang J. Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice. Cell Mol Neurobiol. 2020 Oct;40(7):1155-1164. PMID: 32016638", "BibTeX": "@article{32016638, title={Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.}, author={Yan J and Liu A and Fan H and Qiao L and Wu J and Shen M and Lai X and Huang J}, journal={Cell Mol Neurobiol}, volume={40}, number={7}, pages={1155-1164}}"}}, {"_id": "35466954", "pmid": 35466954, "pmcid": "PMC9398088", "title": "Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT", "journal": "J Parkinsons Dis", "authors": ["Day JO", "Smith S", "Noyce AJ", "Alty J", "Jeffery A", "Chapman R", "Carroll C"], "date": "2022-01-01T00:00:00Z", "doi": "10.3233/JPD-223162", "meta_date_publication": "2022", "meta_volume": "12", "meta_issue": "5", "meta_pages": "1605-1609", "score": 50251.867, "text_hl": "We describe our experience of incorporating two DHTs as secondary/exploratory outcome measures in @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@PD@@@ STAT, a randomised clinical trial of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in people with @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@. ", "citations": {"NLM": "Day JO, Smith S, Noyce AJ, Alty J, Jeffery A, Chapman R, Carroll C. Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT J Parkinsons Dis. 2022;12(5):1605-1609. PMID: 35466954", "BibTeX": "@article{35466954, title={Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT}, author={Day JO and Smith S and Noyce AJ and Alty J and Jeffery A and Chapman R and Carroll C}, journal={J Parkinsons Dis}, volume={12}, number={5}, pages={1605-1609}}"}}, {"_id": "39837893", "pmid": 39837893, "title": "A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson's disease.", "journal": "NPJ Parkinsons Dis", "authors": ["Dou L", "Xu Z", "Xu J", "Zang C", "Su C", "Pieper AA", "Leverenz JB", "Wang F", "Zhu X", "Cummings J", "Cheng F"], "date": "2025-01-22T00:00:00Z", "doi": "10.1038/s41531-025-00870-y", "meta_date_publication": "2025 Jan 22", "meta_volume": "11", "meta_issue": "1", "meta_pages": "22", "score": 50246.277, "text_hl": "Integrating network proximity-based drug repurposing and @SPECIES_9606 @@@patient@@@ electronic health record (EHR) data observations, we identified @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ as being significantly associated with reduced incidence of @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@PD@@@ (hazard ratio (HR) = 0.91 for fall outcome, 95% confidence interval (CI): 0.87-0.94; HR = 0.88 for @DISEASE_Dementia @DISEASE_MESH:D003704 @@@dementia@@@ outcome, 95% CI: 0.86-0.89) after adjusting for 267 covariates. ", "citations": {"NLM": "Dou L, Xu Z, Xu J, Zang C, Su C, Pieper AA, Leverenz JB, Wang F, Zhu X, Cummings J, Cheng F. A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson's disease. NPJ Parkinsons Dis. 2025 Jan 22;11(1):22. PMID: 39837893", "BibTeX": "@article{39837893, title={A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson's disease.}, author={Dou L and Xu Z and Xu J and Zang C and Su C and Pieper AA and Leverenz JB and Wang F and Zhu X and Cummings J and Cheng F}, journal={NPJ Parkinsons Dis}, volume={11}, number={1}, pages={22}}"}}, {"_id": "39704877", "pmid": 39704877, "title": "HMG-CoA reductase inhibitor simvastatin ameliorates trimethyltin neurotoxicity and cognitive impairment through reversal of Alzheimer's-associated markers.", "journal": "Metab Brain Dis", "authors": ["Salari A", "Roghani M", "Khalili M"], "date": "2024-12-20T00:00:00Z", "doi": "10.1007/s11011-024-01515-4", "meta_date_publication": "2024 Dec 20", "meta_volume": "40", "meta_issue": "1", "meta_pages": "74", "score": 50244.883, "text_hl": "The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SV@@@) has shown protective and promising therapeutic effects in @DISEASE_Neurologic_Manifestations @DISEASE_MESH:D009461 @@@neurological disorders@@@ such as @DISEASE_Alzheimer_Disease @DISEASE_MESH:D000544 @@@AD@@@ and @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@. ", "citations": {"NLM": "Salari A, Roghani M, Khalili M. HMG-CoA reductase inhibitor simvastatin ameliorates trimethyltin neurotoxicity and cognitive impairment through reversal of Alzheimer's-associated markers. Metab Brain Dis. 2024 Dec 20;40(1):74. PMID: 39704877", "BibTeX": "@article{39704877, title={HMG-CoA reductase inhibitor simvastatin ameliorates trimethyltin neurotoxicity and cognitive impairment through reversal of Alzheimer's-associated markers.}, author={Salari A and Roghani M and Khalili M}, journal={Metab Brain Dis}, volume={40}, number={1}, pages={74}}"}}, {"_id": "31448832", "pmid": 31448832, "title": "Guided tissue regeneration of intrabony defects with perforated barrier membranes, simvastatin, and EDTA root surface modification: A clinical and biochemical study.", "journal": "J Periodontal Res", "authors": ["Issa DR", "Abdel-Ghaffar KA", "Al-Shahat MA", "Hassan AAA", "Iacono VJ", "Gamal AY"], "date": "2020-01-01T00:00:00Z", "doi": "10.1111/jre.12692", "meta_date_publication": "2020 Jan", "meta_volume": "55", "meta_issue": "1", "meta_pages": "85-95", "score": 50243.4, "text_hl": "The present study was designed to evaluate clinically and biochemically the use of PBM combined with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SMV@@@) gel with and without an associated @CHEMICAL_Edetic_Acid @CHEMICAL_MESH:D004492 @@@EDTA@@@ gel root surface etching as a suggested option that could improve @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SMV@@@ availability and clinical outcomes of PBM. ", "citations": {"NLM": "Issa DR, Abdel-Ghaffar KA, Al-Shahat MA, Hassan AAA, Iacono VJ, Gamal AY. Guided tissue regeneration of intrabony defects with perforated barrier membranes, simvastatin, and EDTA root surface modification: A clinical and biochemical study. J Periodontal Res. 2020 Jan;55(1):85-95. PMID: 31448832", "BibTeX": "@article{31448832, title={Guided tissue regeneration of intrabony defects with perforated barrier membranes, simvastatin, and EDTA root surface modification: A clinical and biochemical study.}, author={Issa DR and Abdel-Ghaffar KA and Al-Shahat MA and Hassan AAA and Iacono VJ and Gamal AY}, journal={J Periodontal Res}, volume={55}, number={1}, pages={85-95}}"}}]}